Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | BLM | P54132 | 2/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | RGS12 | O14924 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296983 | 1.00 | USP2 (0.53) | USP2ALOX15HSD17B10KDM4EHIF1A | |
| SCHEMBL29141540 | 0.92 | USP2 (0.46) | USP2ALOX15HSD17B10KDM4EHIF1A | |
| SCHEMBL9847981 | 0.89 | USP2 (0.50) | USP2ALOX15HSD17B10KDM4EHIF1A | |
| SCHEMBL9851430 | 0.87 | USP2 (0.45) | USP2ALOX15HSD17B10KDM4EHIF1A | |
| SCHEMBL5672308 | 0.87 | USP2 (0.50) | USP2ALOX15HSD17B10KDM4EHIF1A | |
| SCHEMBL5672304 | 0.87 | USP2 (0.50) | USP2ALOX15HSD17B10KDM4EHIF1A | |
| SCHEMBL28551296 | 0.87 | USP2 (0.50) | USP2ALOX15HSD17B10KDM4EHIF1A | |
| SCHEMBL20722991 | 0.84 | USP2 (0.47) | USP2ALOX15HSD17B10KDM4EHIF1A | |
| SCHEMBL20722707 | 0.84 | USP2 (0.47) | USP2ALOX15HSD17B10KDM4EHIF1A | |
| Hydrochloric Acid SCHEMBL20722737 | 0.82 | USP2 (0.46) | USP2ALOX15HSD17B10KDM4EHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161401-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-20250002530-A1 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-01-02 | — | — | US | disclosed |
| US-20240350577-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-10-24 | — | — | US | disclosed |
| US-12065511-B2 | Aromatic-cationic peptides and uses of same | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-02-22 | — | — | US | disclosed |
| US-20240025949-A1 | Beta-Arrestin Effectors and Compositions and Methods of Use Thereof | TREVENA, INC. | 2024-01-25 | — | — | US | disclosed |
| EP-4233887-A1 | METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Stealth BioTherapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-04-06 | — | — | US | disclosed |
| EP-4085920-A1 | METHODS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | Stealth BioTherapeutics Inc. (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-1962959-B1 | NEUROPEPTIDE-2 RECEPTOR-AGONISTS | HOFFMANN LA ROCHE (CH) | 2012-03-14 | — | — | EP | disclosed |
| EP-2326666-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2011-06-01 | — | — | EP | disclosed |
| US-20100184701-A1 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof | TREVENA, INC. | 2010-07-22 | — | — | US | disclosed |
| WO-2010077339-A2 | β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF | TREVENA, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010031707-A1 | NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| EP-1962959-A2 | NEUROPEPTIDE-2 RECEPTOR-AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| US-20070258899-A1 | Diagnostic and therapeutic agents | KARYON-CTT LTD (FI) | 2007-11-08 | — | — | US | disclosed |
| WO-2007113385-A1 | DIAGNOSTIC AND THERAPEUTIC AGENTS | KARYON-CTT LTD (FI) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007065808-A2 | NEUROPEPTIDE-2 RECEPTOR-AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| US-20070135351-A1 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | CONDE-KNAPE KARIN | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135351-A1 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | NPY2R, NPY1R, NPY4R | USP2 2739/4885ALOX15 1425/4885HSD17B10 1955/4885 |
| US-20250002530-A1 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | ARG2, OAT, PDF | USP2 3260/4885ALOX15 2070/4885HSD17B10 2532/4885 |
| US-20250161401-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | MTPN, UTRN, SMN1; SMN2 | USP2 1836/4885ALOX15 3907/4885HSD17B10 2525/4885 |
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | MTPN, CKMT1A; CKMT1B, TFAM | USP2 2999/4885ALOX15 2511/4885HSD17B10 1640/4885 |
| US-20230109564-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | MTPN, UTRN, SMN1; SMN2 | USP2 1836/4885ALOX15 3907/4885HSD17B10 2525/4885 |
| US-20070258899-A1 | Diagnostic and therapeutic agents | YBX1, MLX, TPX2 | USP2 3792/4885ALOX15 4182/4885HSD17B10 4778/4885 |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | S100A10, SPG11, TMSB10 | USP2 3048/4885ALOX15 3749/4885HSD17B10 2317/4885 |
| US-12065511-B2 | Aromatic-cationic peptides and uses of same | ARG2, OAT, PDF | USP2 3260/4885ALOX15 2070/4885HSD17B10 2532/4885 |
| US-20240350577-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING DOMINANT OPTIC ATROPHY | CRYAA, CRYAB, PRPH | USP2 2211/4885ALOX15 1975/4885HSD17B10 2321/4885 |
| US-20240025949-A1 | Beta-Arrestin Effectors and Compositions and Methods of Use Thereof | ARRB1, FGB, SARS1 | USP2 2017/4885ALOX15 3659/4885HSD17B10 3697/4885 |
| US-20100184701-A1 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof | ARRB1, ADRB1, ADRB3 | USP2 1527/4885ALOX15 3979/4885HSD17B10 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.